Transaction #13889 · Form 4 · 0001193125-25-304212
Metagenomi Therapeutics, Inc. · Stock award · Common Stock
Metagenomi Therapeutics, Inc. · Transacted December 1, 2025 · Filed December 1, 2025
What does this filing report?
An SEC Form 4 filing for Metagenomi Therapeutics, Inc. records a stock award involving Common Stock on December 1, 2025. The reported quantity was 211,000. The filing date is December 1, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001785279
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 211,000
- Reported price
- 1.6
- Reference value
- 337,600
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 565,441
- Ownership description
- Not reported
- SEC acceptance time
- Dec 1, 2025, 7:28 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Irish Jian ↗
Chief Executive Officer · Director
CIK 0001995697
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units ("RSUs") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person.
- F2
- Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 30, 2025 and 1,500 shares acquired under the Company's ESPP on November 28, 2025.
- F3
- These shares represent RSUs. 25% of the RSUs shall vest on December 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- F4
- These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- F5
- 25% of the shares subject to this option shall vest and become exercisable on November 6, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.